NASDAQ: AIKIAikido Pharma Inc Stock
$3.53+0.00 (+0%)
Updated Dec 8, 2022
AIKI Price
$3.53
Fair Value Price
$43.23
Market Cap
$19.35M
52 Week Low
$3.31
52 Week High
$11.90
P/E
-0.91x
P/B
0.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$11M
Beta
-0.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIKI Overview
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AIKI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIKI ($3.53) is undervalued by 91.84% relative to our estimate of its Fair Value price of $43.23 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AIKI ($3.53) is significantly undervalued by 91.84% relative to our estimate of its Fair Value price of $43.23 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AIKI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AIKI due diligence checks available for Premium users.
Be the first to know about important AIKI news, forecast changes, insider trades & much more!
AIKI News
Valuation
AIKI fair value
Fair Value of AIKI stock based on Discounted Cash Flow (DCF)
Price
$3.53
Fair Value
$43.23
Undervalued by
91.83%
AIKI ($3.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AIKI ($3.53) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AIKI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AIKI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.91x
Industry
13.31x
Market
21.39x
AIKI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
4.98x
AIKI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIKI's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.2M
Profit Margin
0%
AIKI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$84.4M
Liabilities
$2.6M
Debt to equity
0.03
AIKI's short-term assets ($56.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIKI's short-term assets ($56.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIKI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIKI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$681.0k
Financing
-$751.0k
AIKI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIKI vs Biotech Stocks
Aikido Pharma Stock FAQ
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.